
-
Van Niekerk enjoys second wind in Tokyo after injury nightmare
-
American Moon wins third straight world pole vault gold
-
King gives Trump royal welcome on UK state visit
-
Man Utd post sixth straight annual loss despite record revenues
-
Australian teen Gout Gout revels in world championships debut
-
AI may boost global trade value by nearly 40%: WTO
-
New Zealand star Miller out of Women's Rugby World Cup semi-final
-
Lyles and Gout Gout advance to world 200m semi-finals
-
S.Africa commission begins probe into alleged links between politics and crime
-
PSG women in audacious bid to sign Barca's Putellas
-
Jefferson-Wooden eases into world 200m semis and sets sights on being next Fraser-Pryce
-
Germany's Merz vows 'autumn of reforms' in turbulent times
-
EU says India's Russian oil purchases, military drills hinder closer ties
-
Gold worth 600,000 euros stolen in Paris museum heist
-
Top music body says AI firms guilty of 'wilful' copyright theft
-
Trump gets royal treatment on UK state visit
-
Ostrich and emu ancestor could fly, scientists discover
-
Former boxing world champion Hatton 'excited for the future' before death: family
-
Stocks, dollar calm before expected US rate cut
-
After mass Nepal jailbreak, some prisoners surrender
-
Poison killed Putin critic Navalny, wife says
-
Australia coach expects Cummins to play 'key part' in Ashes
-
Hong Kong leader plans to fast-track border mega-project
-
Ben & Jerry's co-founder quits, says independence 'gone'
-
Erasmus keeps faith with Springbok squad after record All Blacks win
-
Hong Kong leader unveils plan to boost growth with border mega-project, AI push
-
Israel says opening new route for Gazans fleeing embattled city
-
New Zealand's historic athletics worlds a decade in the making
-
Trump to get royal treatment on UK state visit
-
Benfica sack Lage after shock defeat, Mourinho next?
-
Israel says to open new route for Gazans fleeing embattled city
-
Nestle share price slips as chairman follows CEO out the door
-
German suspect in Madeleine McCann case freed from prison
-
US tennis star Townsend apologises for 'crazy' Chinese food post
-
Peru evacuates 1,600 tourists from Machu Picchu amid protest
-
Nepal mourns its dead after anti-corruption protests
-
UK inflation stable ahead of central bank rate call
-
India checks Maoist rebel offer of suspending armed struggle
-
Israel to open new route for Gazans fleeing besieged city
-
Lower shipments to US, China weigh on Singapore August exports
-
Inside the hunt for the suspect in Charlie Kirk's killing
-
Junta accused of coveting power in crucial Guinea referendum
-
TV writer Hagai Levi: boycott risks hitting Israel's critical voices
-
Sri Lanka to ban predatory pet fish to protect ecosystems
-
'Genius' De Bruyne leads Napoli in emotional return to Man City
-
World number one Sabalenka out of China Open with injury
-
Estimated 16,500 climate change deaths during Europe summer: study
-
'Fifa' successor 'FC 26' polishes the beautiful game
-
Park Chan-wook's murder comedy to open Asia's biggest film festival
-
India's gaming fans eye illegal sites after gambling ban

US tells pharmas to make Covid boosters targeting BA.4 and BA.5
The US Food and Drug Administration on Thursday told vaccine makers that Covid boosters for this fall and winter should include components targeting the BA.4 and BA.5 sublineages of Omicron.
Earlier this week, a panel of medical experts convened by the agency voted in favor of updating Covid vaccines against Omicron, with most indicating they would favor shots that target the latest iterations rather than its original form, BA.1, fearing the latter would be too out-of-date.
BA.4 and BA.5, which are more transmissible and immune evasive, now comprise more than 52 percent of US Covid cases, according to an official tracker.
"We have advised manufacturers seeking to update their Covid-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine," the FDA said in a statement.
These vaccines would also need to target the original Wuhan strain, in order to increase the breadth of immune response.
Pfizer and Moderna, which produce messenger RNA Covid vaccines, have developed and tested vaccines against BA.1, and representatives of both companies indicated during the experts' meeting they would need around three months to produce BA.4 and BA.5 vaccines at scale.
Pfizer shared early results showing its BA.4/5 vaccine produced a strong antibody response in mice, but it hasn't yet been trialed in humans.
Novavax, which makes a protein subunit vaccine, said it could offer BA.4/5 vaccines by the end of the year.
The FDA said in its new statement that the companies would need to submit human data prior to authorization.
The "primary series" or first shots a person receives would remain against the original strain, the FDA added.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sublineages have dominated throughout 2022, to the point it comprises the vast majority of all Covid in the world, FDA official Jerry Weir told the expert meeting this week.
This makes it more likely that the virus's future evolution will also occur along the Omicron branch of the Covid family tree, he added.
Earlier this month, the World Health Organization also recommended the use of Omicron boosters after a primary series against the original strain.
D.Sawyer--AMWN